{"id":"W4411325981","doi":"10.1002/hon.70094_443","title":"443 | A PHASE 1 STUDY OF PRT2527, A SELECTIVE CDK9 INHIBITOR, AS MONOTHERAPY AND IN COMBINATION WITH ZANUBRUTINIB IN RELAPSED/REFRACTORY LYMPHOID MALIGNANCIES: UPDATED ANALYSIS","year":2025,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University; Jewish General Hospital","funders":"BeiGene; Gilead Sciences; Merck KGaA; Regeneron Pharmaceuticals; Pharmacyclics; Genentech; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb; TG Therapeutics; Amgen","keywords":"Refractory (planetary science); Medicine; Oncology; Internal medicine; Cancer research; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00183049,0.0006061422,0.001040507,0.0005329011,0.0001829296,0.0008220506,0.0006075166,0.0004792495,0.003637015],"category_scores_gemma":[0.000765954,0.0002828047,0.001249524,0.0007525256,0.000178776,0.0004029371,0.0001800594,0.0008653146,0.0006803111],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009506,"about_ca_system_score_gemma":0.001189957,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002147786,"about_ca_topic_score_gemma":0.006944973,"domain_scores_codex":[0.9995866,0.0001597432,0.00004120991,0.00007015566,0.00009466935,0.00004756653],"domain_scores_gemma":[0.9995764,0.0001193213,0.0001286938,0.00002609107,0.0000705917,0.00007899038],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.1021263,0.005087343,0.05293448,0.005219307,0.008091369,0.0006219806,0.0001798743,0.004128393,0.05494629,0.0004344442,0.03670222,0.729528],"study_design_scores_gemma":[0.1785272,0.199205,0.3246545,0.001497615,0.0271389,0.004689551,0.000210851,0.005590891,0.02594387,0.0008007142,0.2315428,0.0001981816],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8179842,0.122313,0.003649519,0.002858703,0.0003580393,0.003409029,0.03040488,0.0004118312,0.01861078],"genre_scores_gemma":[0.8969294,0.04931454,0.004332579,0.002963365,0.0003659382,0.001077983,0.0380304,0.00008450382,0.006901258],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003637015,"threshold_uncertainty_score":0.01216704,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02042136548820413,"score_gpt":0.366227967127734,"score_spread":0.3458066016395299,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}